Morningstar

Artelo Biosciences Inc ARTL

Stock XNAS Rating as of Nov 3, 2026

News

Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain

GlobeNewswire Oct 29, 2026, 1:00:00 PM
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain

GlobeNewswire Oct 26, 2026, 11:55:00 AM
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

GlobeNewswire Oct 7, 2026, 12:48:00 PM
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

GlobeNewswire Sep 23, 2026, 11:33:00 AM
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

GlobeNewswire Sep 16, 2026, 11:30:00 AM
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire Sep 8, 2026, 1:00:00 PM
Artelo Biosciences Announces Reverse Stock Split

GlobeNewswire Aug 27, 2026, 12:00:00 PM
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

GlobeNewswire Aug 20, 2026, 12:52:00 PM
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

GlobeNewswire Aug 17, 2026, 12:52:00 PM
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

GlobeNewswire Aug 13, 2026, 12:00:00 PM
Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma

GlobeNewswire Aug 10, 2026, 12:47:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.